Project Grant R01HL175086
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Texas Southwestern Medical Center a $249,000 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective August 1, 2025, through June 30, 2028, to conduct research investigating the mechanisms of dyspnea on exertion (DOE) and exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). The research will examine how obesity-related mechanical...
- Federal Project Grant Award Summary Mayo Clinic received a $745,851 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2030. The award supports a five-year research initiative examining the integration of inspiratory muscle training (IMT) into cardiac rehabilitation (CR) protocols for patients with heart failure with reduced ejection fraction (HFrEF). The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a research project examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling. The project, which will extend through February 28, 2031, investigates whether systolic blood pressure indexed to oxygen consumption...
- The University of Iowa received a $612,186 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion scheduled for May 31, 2029. The research investigates the role of lysosomal dysfunction in heart failure with preserved ejection fraction (HFpEF), specifically examining how gamma interferon-inducible thiol reductase (GILT) dysfunction contributes to cardiac immuno-metabolic...
- The University of Pittsburgh was awarded a $633,045 project grant by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the pathogenic mechanisms and therapeutic approaches for exercise intolerance in post-acute sequelae of COVID-19 (PASC). The project aims to elucidate the molecular drivers of exercise intolerance in PASC patients, leveraging the university's expertise in evaluating PASC patients at their post-COVID recovery clinic. Key...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $721,237 Project Grant to the University of California, Los Angeles (UCLA) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the neural mechanisms by which inspiratory muscle training (IMT) reduces blood pressure in patients with obstructive sleep apnea (OSA). The four-year research initiative, effective September 1, 2025 through June 30, 2029, will examine whether IMT lowers...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $242,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for August 31, 2027. This feasibility study (R03 mechanism) implements arteriovenous blood sampling techniques to measure regional metabolic changes in the heart and legs during submaximal exercise...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $173,352 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for June 30, 2030. Under Principal Investigator Dr. Andrew Perry's direction, the award funds research investigating the molecular and proteomic underpinnings of frailty and functional limitations in heart failure with...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $774,997 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through May 31, 2029. The award funds research investigating the contribution of medullary pre-sympathetic neurons to breathing disorders and autonomic dysfunction in heart failure with preserved ejection fraction...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $999,110 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion anticipated by May 31, 2030. The grant supports a comprehensive research initiative investigating cellular heterogeneity in mitochondrial calcium dynamics in heart failure with preserved ejection fraction (HFPEF). The research...
PERIPHERAL MECHANISMS OF EXERCISE INTOLERANCE IN HFPEF - PROJECT SUMMARY/ABSTRACT: THE HALLMARK FEATURES OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) ARE EXERCISE INTOLERANCE AND EXERTIONAL SYMPTOMOLOGY. IT IS NOW CLEAR THAT THE PATHOPHYSIOLOGY OF EXERCISE INTOLERANCE INVOLVES MULTIPLE PHYSIOLOGICAL SYSTEMS IN HFPEF WITH PERIPHERAL ('NON-CARDIAC') ABNORMALITIES HAVING A CRITICAL ROLE. LOCOMOTOR MUSCLE AFFERENT FEEDBACK REFLEXES ARE NECESSARY FOR THE NORMAL LOCOMOTOR MUSCLE BLOOD FLOW AND VENTILATORY RESPONSES TO EXERCISE IN HEALTHY ADULTS. HOWEVER, THESE LOCOMOTOR MUSCLE AFFERENT REFLEXES APPEAR TO BE 'OVERACTIVE' WITH HFPEF IMPAIRING LOCOMOTOR BLOOD FLOW AND EXAGGERATING THE VENTILATORY RESPONSE. ADDITIONALLY, PULMONARY SYSTEM ALTERATIONS AND INSPIRATORY MUSCLE METABOLIC INEFFICIENCY IN HFPEF NECESSITATE AN EXAGGERATED INSPIRATORY MUSCLE BLOOD FLOW DEMAND DURING EXERCISE. IMPORTANTLY, HFPEF PATIENTS ARE UNABLE TO MEET THIS EXAGGERATED INSPIRATORY MUSCLE BLOOD FLOW DEMAND DURING EXERCISE. THIS EXAGGERATED DEFICIT BETWEEN INSPIRATORY MUSCLE BLOOD FLOW DEMAND AND BLOOD FLOW RESPONSE TO EXERCISE IN HFPEF MAY PREDISPOSE THEM TO EXERCISE INTOLERANCE AND EXERTIONAL DYSPNEA. OUR SCIENTIFIC PREMISE IS THAT LOCOMOTOR AND INSPIRATORY MUSCLE PATHOPHYSIOLOGIC MECHANISMS CONTRIBUTE TO THE WELL DESCRIBED EXERCISE INTOLERANCE AND EXERTIONAL SYMPTOMS IN HFPEF PATIENTS. THE SPECIFIC AIMS THAT WILL BE EXPLORED IN THIS PROPOSAL INCLUDE: 1) TO TEST IF LOCOMOTOR SKELETAL MUSCLE AFFERENT FEEDBACK REFLEXES CONTRIBUTE TO THE ABNORMAL CARDIOVASCULAR AND VENTILATORY FUNCTION DURING EXERCISE IN HFPEF, AND 2) TO TEST IF INSPIRATORY MUSCLE TRAINING REDUCES THE EXAGGERATED INSPIRATORY MUSCLE BLOOD FLOW DEMAND IN HFPEF AND IMPROVES EXERCISE TOLERANCE AND EXERTIONAL SYMPTOMOLOGY IN THESE PATIENTS. BOTH AIMS ARE FRAMED WITH TESTABLE HYPOTHESES AND CLEARLY ASSOCIATED WITH THE EXPERIMENTAL PROTOCOL AND STATISTICAL ANALYSIS PLAN. OUR INTEGRATIVE, HIGHLY COLLABORATIVE RESEARCH TEAM HAS THE INTELLECTUAL AND TECHNICAL EXPERTISE, ESTABLISHED INFRASTRUCTURE, AND CLEARLY DEMONSTRATE HIGH FEASIBILITY IN PERFORMING ALL FACETS OF THESE STUDIES TO ADDRESS AND INTERPRET THE AIMS WE HAVE PROPOSED. OUR PROPOSAL ADDRESSES AN IMPORTANT PROBLEM BY FOCUSING ON IDEAS THAT ARE A SIGNIFICANT DEPARTURE FROM CURRENT PARADIGMS ON EXERCISE INTOLERANCE AND EXERTIONAL SYMPTOMOLOGY IN HFPEF PATIENTS. OUR PRELIMINARY DATA AND REVIEW OF THE RIGOR OF PRIOR RESEARCH SUPPORTING OUR AIMS PROVIDE STRONG JUSTIFICATION FOR OUR INNOVATIVE EXPERIMENTAL DESIGN, GOLD STANDARD TECHNIQUES, AND INSPIRATORY MUSCLE TRAINING (AN INTERVENTION WITH HIGH CLINICAL UTILITY) TO REVEAL HOW LOCOMOTOR AND INSPIRATORY MUSCLE DYSFUNCTION IMPAIR EXERCISE TOLERANCE AND EXERTIONAL DYSPNEA IN PATIENTS WITH HFPEF. FINALLY, WE HAVE ALIGNED OUR SCIENTIFIC PREMISE, AIMS, AND ASSOCIATED HYPOTHESES WITH THE NHLBI RESEARCH PRIORITIES AND THE CURRENT NIH REVIEW CRITERIA THAT EMPHASIZES SIGNIFICANCE, IMPACT, AND INNOVATION FOR R01 APPLICATIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $767.4k | 5/27/25 | ||
| Not listed | $0 | 5/2/25 | ||
| Not listed | $0 | 5/2/25 | ||
| Not listed | $0 | 8/21/24 | ||
| Not listed | $0 | 8/21/24 |